The alterations in PI3K/AKT/mTOR level in Mecp2 KO mice can be restored using IGF1, and treatment with PI3K antagonists rescue FXS defects (Gross et al., 2010; Ricciardi et al., 2011; Yuan et al., 2020). The gene discussed is MECP2; the disease is fragile X syndrome.